NICE Guidelines for FeNO Testing recommend Bedfont NObreath®

April 3, 2014 - PRLog -- The final diagnostics guidance on Measuring fractional exhaled nitric oxide concentration in asthma, recommending the use of Bedfont NObreath^® have now been published.

The Bedfont NObreath^® is mentioned in new guidance recommending the use of simple, non-invasive testing to help diagnose and treat asthma (http://www.webmd.boots.com/asthma/default.htm).  The report is produced by NICE, the National Institute for Health and Care Excellence.

http://guidance.nice.org.uk/DG12

Mr Jason Smith, Commercial Manager at Bedfont Scientific said “The NObreath^® monitor enables doctors, asthma specialists, GP’s and respiratory specialists to comply with ATS and ERS guidelines when testing for FeNO levels in asthma patients.   Asthma patients can easily be tested and correctly assessed, thus saving time and reducing costs.

The battery powered monitor has been specifically designed to be highly portable.  A large graphical colour touch screen and rapid start-up allows easy use by people of all ages.”

Airway inflammation is a central process in asthma and other lung diseases

Being able to measure this inflammation and monitor the patient’s reaction to medication is regarded as a gold standard in the management of respiratory diseases. It is increasingly recognised that the measurement of Feno in particular constitutes a novel way to monitor separate aspects of diseases. These include asthma, COPD and interstitial lung diseases, that are not assessed by other means, such as lung function.

Feno measurements to evaluate airway inflammation in asthma represents a significant advance in respiratory medicine, but until now this has been an expensive test to deliver in everyday practice.

For more information and clinical papers on the NObreath^® please visit www.bedfont.com or call a member of our Sales Team on 01622 851122.